Cerity Partners LLC Buys 5,467 Shares of Danaher Corporation $DHR

Cerity Partners LLC increased its stake in shares of Danaher Corporation (NYSE:DHR) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 342,876 shares of the conglomerate’s stock after purchasing an additional 5,467 shares during the quarter. Cerity Partners LLC’s holdings in Danaher were worth $67,733,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ceredex Value Advisors LLC raised its position in shares of Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after acquiring an additional 3,862 shares during the last quarter. Chicago Capital LLC boosted its holdings in Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after acquiring an additional 1,391 shares during the last quarter. Weitz Investment Management Inc. increased its position in Danaher by 6.1% in the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after purchasing an additional 30,300 shares during the period. UniSuper Management Pty Ltd increased its position in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after purchasing an additional 2,667 shares during the period. Finally, Nvwm LLC raised its holdings in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after purchasing an additional 1,204 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is owned by company insiders.

Danaher Stock Performance

DHR opened at $226.20 on Monday. The company has a market capitalization of $159.78 billion, a price-to-earnings ratio of 46.64, a P/E/G ratio of 4.39 and a beta of 0.89. The business’s 50-day moving average price is $216.22 and its two-hundred day moving average price is $204.48. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.71 EPS. Equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Analyst Ratings Changes

A number of equities analysts have issued reports on DHR shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft raised their price target on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Twenty investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.75.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.